T. Ishikawa

TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice

Y. Shimizu, Mitsuhiro Ito, H. Yukitake, 2019, Pharmacology Biochemistry and Behavior.

Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model

H. Kimura, Ayumi Kawano, T. Ishikawa, 2022, Pharmacology Biochemistry and Behavior.

Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist

Y. Shimizu, K. Fukuda, N. Tokunaga, 2022, ACS medicinal chemistry letters.

Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients

C. Davies, E. Mignot, Y. Dauvilliers, 2022, Proceedings of the National Academy of Sciences of the United States of America.

Orexin 2 receptor‐selective agonist danavorexton (TAK‐925) promotes wakefulness in non‐human primates and healthy individuals

Yaming Hang, H. Faessel, H. Yukitake, 2023, Journal of sleep research.

0055 An Orexin 2 Receptor-selective Agonist, TAK-925, Ameliorates Narcolepsy-like Symptoms and Obesity in Orexin/ataxin-3 Transgenic Mice

H. Yukitake, H. Kimura, Motohisa Suzuki, 2019, Sleep.

TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy

K. Tohyama, H. Kimura, T. Koike, 2023, The Journal of Pharmacology and Experimental Therapeutics.